New combo therapy aims to shrink esophageal tumors before surgery

NCT ID NCT07403435

Not yet recruiting Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Feb 17, 2026 · Last updated May 24, 2026 · Updated 12 times

Summary

This study tests a new approach for people with a type of esophageal cancer that can be surgically removed. Before surgery, participants receive a short course of radiation, followed by three cycles of an immunotherapy drug (serplulimab) plus standard chemotherapy. The goal is to see if this combination can eliminate or greatly reduce the cancer before the operation. The trial involves 22 adults aged 18-75 with good overall health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)